Welcome to our dedicated page for Inspira Tech news (Ticker: IINNW), a resource for investors and traders seeking the latest updates and insights on Inspira Tech stock.
News for Inspira Technologies Oxy B.H.N. Ltd. (IINN, IINNW) centers on its development and deployment of respiratory support and extracorporeal life support technologies. The company regularly issues updates on the INSPIRA ART platform, the INSPIRA ART100 cardiopulmonary bypass system, and the HYLA real-time blood sensor, providing insight into how these technologies are progressing from development to clinical and commercial use.
Investors and healthcare professionals following Inspira’s news can expect coverage of product feature enhancements, such as new support functions for the FDA-cleared INSPIRA ART100 system designed to assist medical teams through setup and alarm troubleshooting. Announcements also describe clinical integration plans, including deliveries of ART100 systems to distributors, preparation for deployment at leading U.S. hospitals, and showcasing the technology at major healthcare exhibitions.
Company news also highlights collaborations and manufacturing developments, such as the establishment of a dedicated production line with a specialized medical device manufacturer for components used in extracorporeal circulation. Updates on the HYLA blood sensor often focus on its role in continuous blood monitoring and its expansion into immediate personalized blood lab testing aimed at rapid detection of potential life-threatening conditions.
Capital markets and corporate governance items appear in Inspira’s news flow as well, including private placement announcements, sales agreement updates, and board-level changes. Together, these releases provide a view into Inspira’s product roadmap, regulatory milestones, commercialization efforts, and financing activities. This news page aggregates those developments so readers can follow how the company’s life support and respiratory treatment technologies evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN)(NASDAQ:IINNW) is set to present at the 2023 Planet MicroCap Showcase in Las Vegas on April 26, 2023, at 14:30 CST. Joe Hayon, President and Co-Founder, will lead the presentation. Interested parties can access the live presentation via the provided webcast link. Registration for the event is necessary, which can be done here. Additionally, one-on-one virtual meetings can be scheduled with Joe throughout May by using this link. Inspira Technologies focuses on innovative respiratory treatments, particularly its Augmented Respiration Technology, aimed at improving patient outcomes while minimizing the use of invasive mechanical ventilation.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) reported its financial results for the year ended December 31, 2022. The company has $13.9 million in cash, a decrease from $23.7 million in 2021, with shareholders' equity falling to $12.8 million from $20.3 million. R&D expenses increased to $8 million from $3.9 million in the previous year. The net loss showed improvement at $10.3 million compared to $17 million in 2021. The company plans to submit its ALICE device for FDA approval in H2 2023 and is conducting clinical studies for its HYLA blood sensor. Inspira continues to advance its INSPIRA ART system aimed at non-invasive respiratory treatment.